Phaseline

Companies › ReGenTree

ReGenTree: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Ophthalmology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RGN-259
Thymosin beta 4 (Tβ4) analogue
TB4Phase 3Neurotrophic Keratopathy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05555589RGN-259Phase 3Neurotrophic KeratopathyOphthalmologyJul 2026

Targets

TB4 (1)

Companies with the same targets

–

Companies built like this

Ocus Innovation Ireland Ocumension Therapeutics (Suzhou) Alkeus Pharmaceuticals Laboratorios Sophia S.A de C.V. Cloudbreak Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.